The use of a humanized anti-CD26 mAb may therefore be a rational therapy for patients with malignant mesothelioma.
Raleigh, NC (PRWEB) July 22, 2016
Mesothelioma patients in Japan will soon be invited to help test a new drug that has shown promise in animal testing. Surviving Mesothelioma has more on the trial announcement. Click here to read it now.
Scientists at Juntendo University have announced their intention to launch a clinical trial of the monoclonal antibody (mAb) YS110 “in the very near future”. Their previous studies of the drug in mice found that it slowed mesothelioma tumor growth by 20 percent in 48 hours.
“The use of a humanized anti-CD26 mAb may therefore be a rational therapy for patients with malignant mesothelioma,” writes study author Chikao Morimoto.
Dr. Morimoto and his colleagues estimate that as many as 85 percent of mesothelioma patients have tumors that overexpress the protein CD26. Normal mesothelial cells do not express this protein.
“We at Surviving Mesothelioma are closely following the progress of YS110 and its impact on mesothelioma treatment,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “Given the limited number of treatment option for people with refractory malignant mesothelioma, we are encouraged by the preliminary study results on this drug.”
To read more about the role of CD26 in mesothelioma growth and development, as well as learn about the upcoming clinical trial, see Investigational Mesothelioma Drug to be Tested in Human Patients, now available on the Surviving Mesothelioma website.
Morimoto, Chikao and Ohnuma, K, “Development of New Therapy for Malignant Mesothelioma Based on CD26 Molecule:, July 2015, Cancer & Chemotherapy, pp. 855-862, http://www.ncbi.nlm.nih.gov/pubmed/27431629